OKL-1014

**OKL-1014** is an investigational preclinical therapeutic candidate from Okklo Life Sciences being developed for **Niemann-Pick disease type C**, a rare lysosomal storage disorder. Publicly available information indicates that Okklo's platform is based on **cyclodextrin-derived therapeutic technologies**, and OKL-1014 appears to be one of these cyclodextrin-based drug candidates intended for lysosomal disease applications. However, the precise chemical identity, molecular structure, route, dosage form, and validated target-level mechanism of action for OKL-1014 have not been clearly disclosed in accessible primary public sources, so the mechanism should currently be regarded as incompletely characterized from open-source data.